This strategic partnership signals Soframycin’s official entry into the digital space, marking a new chapter for the iconic brand known for treating wounds, cuts, and burns for generations. BigTrunk will spearhead Soframycin’s end-to-end digital strategy, including social media management, content creation, and data-driven campaigns aimed at strengthening the brand’s presence across India.
“As we take Soframycin into its next chapter of growth, embracing digital media is not just a strategy but a necessity. We wanted a partner who could translate our scientific credibility into engaging, relatable content for today’s audience. BigTrunk’s deep understanding of healthcare communications and digital behavior makes them the ideal partner to build meaningful narratives around wound care, trust, and wellbeing.”
Encube Ethicals, established in 1998, is a global pharmaceutical leader in topical formulations, with operations in over 50 countries and a robust team of 1,400+ professionals, including 200+ R&D specialists. Backed by this pharmaceutical legacy, Soframycin enters the digital age with a strong foundation in science, quality, and care.
“Soframycin is more than a product—it’s a legacy deeply rooted in care and science. We’re excited to take on this responsibility of guiding a heritage brand into the digital world. Our focus will be on creating contextual storytelling and purpose-driven campaigns that bring Soframycin closer to Indian families, both old and new.”
This collaboration is set to redefine Soframycin’s brand presence online, connecting with both new and loyal users through engaging, credible, and informative content that mirrors its long-standing reputation in Indian households.
Read more: Azerion Promotes Ava Moran to Newly Created Role of EVP, Country Manager, North America
